Articles related to OVARIAN CANCER

Referral rates for newly diagnosed gynecological malignancy occurred in only 14.6% of eligible patients despite attendance rates of 81.7% when referrals were made.

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.

Explore the transformative potential of antibody-drug conjugates (ADCs) in cancer therapy, offering targeted treatments with reduced side effects. Recent approvals and ongoing trials signify a significant shift towards precision medicine in oncology.

Virginia Commonwealth University’s latest research introduces a novel, urine-based test for ovarian cancer, utilizing nanotechnology to identify specific peptides, offering a new avenue for early detection and enhancing patient care strategies.